1. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: WHO, 1997.
2. Biddle S, García Bengoechea E, Pedisic Z, et al. Screen Time, Other Sedentary Behaviours, and Obesity Risk in Adults: A Review of Reviews. Curr Obes Rep. 2017;6(2):134-47.
3. Arroyo-Johnson C, Mincey KD. Obesity Epidemiology Worldwide. Gastroenterol Clin North Am. 2016;45(4):571-9.
4. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017;376(3):254-66.
5. Yeo G, Heisler L. Unraveling the brain regulation of appetite: lessons from genetics. Nat Neurosci. 2012;15(10):1343-9.
6. Lam D, Garfield A, Marston O, et al. Brain serotonin system in the coordination of food intake and body weight. Pharmacol Biochem Behav. 2010;97(1):84-91.
7. Campbell E, Franks A, Joseph P. Adolescent obesity in the past decade: A systematic review of genetics and determinants of food choice. J Am Assoc Nurse Pract. 2019;31(6):344-51.
8. Zhi C, Huang J, Wang J, et al. Connection between gut microbiome and the development of obesity. Eur J Clin Microbiol Infect Dis. 2019; Jul 31. DOI:10.1007/s10096-019-03623-x
9. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-92.
10. Bastard J, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4-12.
11. Montanari T, Pošćić N, Colitti M. Factors involved in white-to-brown adipose tissue conversion and in thermogenesis: a review. Obes Rev. 2017;18(5):495-513.
12. Fernández-Verdejo R, Marlatt K, Ravussin E, Galgani J. Contribution of brown adipose tissue to human energy metabolism. Mol Aspects Med. 2019; Jul 16. DOI:10.1016/j.mam.2019.07.003
13. Must A, Spadano J, Coakley E, et al. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-9.
14. Guh D, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.
15. Lenz M, Richter T, Muhlhauser I. The morbidity and mortality associated with overweight and obesity in adulthood: a systematic review. Dtsch Arztebl Int. 2009;106:641-8.
16. Alberti K, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome a new worldwide definition. Lancet. 2005;366:1059-62.
17. Available at: https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight
18. Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32(9):1431-7.
19. Дедов И.И., Шестакова М.В., Галстян Г.Р. Распространенность сахарного диабета 2 типа у взрослого населения России (исследование NATION). Сахарный диабет. 2016;19(2):104-12 
[Dedov II, Shestakova MV, Galstian GR. Rasprostranennost’ sakharnogo diabeta 2 tipa u vzroslogo naseleniia Rossii (issledovanie NATION). Sakharnyi diabet. 2016;19(2):104-12 
(in Russian)].
20. Ожирение: этиология, патогенез, клинические аспекты. Под ред. И.И. Дедова, Г.А. Мельниченко. М.: Медицинское информационное агентство, 2004; с. 16-21 [Obesity: etiology, pathogenesis, clinical aspects. Edited by I.I. Dedov, G.A. Melnichenko. Moscow: Medical Information Agency, 2004; р. 16-21 (in Russian)].
21. Garvey W, Garber A, Mechanick J, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease. Endocr Pract. 2014;20:977-89.
22. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. Geneva: World Health Organization, 1995; р. 329.
23. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205-11.
24. Swinburn BA, Craig PL, Daniel R, Dent DP, Strauss BJ. Body composition differences between Polynesians and Caucasians assessed by bioelectrical impedance. Int J Obes Relat Metab Disord. 1996;20:889-94.
25. Forbes GB, Reina JC. Adult lean body mass decline with age: some longitudinal observations. Metabolism. 1970;19:653-63.
26. Rolland-Cachera MF, Cole TJ, Sempé M, et al. Body mass index variations – centiles from birth to 87 years. Eur J Clin Nutr. 1991;45:13-21.
27. Ross R, Shaw KD, Rissanen J, et al. Sex differences in lean and adipose tissue distribution by magnetic resonance imaging: anthropometric relationships. Am J Clin Nutr. 1994;59:1277-85.
28. Norgan NG, Jones PRM. The effect of standardizing the body mass index for relative sitting height. Int J Obes Relat Metab Disord. 1995;19:206-8.
29. Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. Br Med J. 1995;311:158-61.
30. Han TS, et al. Waist circumference relates to intra-abdominal fat mass better than waist: hip ratio in women. Proceedings of the Nutrition Society. 1995;54:152A.
31. Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460-8.
32. Ross R, Léger L, Morris D, et al. Quantification of adipose tissue by MRI: relationship with anthropometric variables. J Appl Physiol. 1992;72:787-95.
33. Lean MEJ, Han TS, Deurenberg P. Predicting body composition by densitometry from simple anthropometric measurements. Am J Clin Nutr. 1996;63:4-14.
34. Han TS, Richmond P, Avenell A, Lean ME. Waist circumference reduction and cardiovascular benefits during weight loss in women. Int J Obes Relat Metab Disord. 1997;21:127-34.
35. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557-67.
36. Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, Di Angelantonio E, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085-95.
37. Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25(9):1751-62. DOI:10.1097/HJH.0b013e3282f0580f
38. Masa JF, Pépin JL, Borel JC, et al. Obesity hypoventilation syndrome. Eur Respir Rev. 2019;28(151). pii: 180097
39. Macavei VM, Spurling KJ, Loft J, Makker HK. Diagnostic predictors of obesity-hypoventilation syndrome in patients suspected of having sleep disordered breathing. J Clin Sleep Med. 2013;9:879-84.
40. Camilleri M, Malhi H, Acosta A. Gastrointestinal Complications of Obesity. Gastroenterology. 2017;152(7):1656-70.
41. Khatua B, El-Kurdi B, Singh VP. Obesity and pancreatitis. Curr Opin Gastroenterol. 2017;33(5):374-82.
42. Escobar-Morreale HF, Santacruz E, Luque-Ramírez M, Botella Carretero JI. Prevalence of “obesity-associated gonadal dysfunction” in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Hum Reprod Update. 2017; 23 (4): 390–408.
43. Daniel E, Newell-Price J. Cushing’s syndrome. Medicine. 2017;45(8):475-9.
44. Stuart CA, Driscoll MS, Lundquist KF, et al. Acanthosis nigricans. J Basic Clin Physiol Pharmacol. 1998;9(2-4):407-18.
45. Rohde K, Keller M, la Cour Poulsen L, et al. Genetics and epigenetics in obesity. Metabolism. 2019;92:37-50.
46. Mirzababaei A, Mozaffari H, Shab-Bidar S, et al. Risk of hypertension among different metabolic phenotypes: a systematic review and meta-analysis of prospective cohort studies. J Hum Hypertens. 2019;33(5):365-77.
47. Deng G, Yin L, Liu W, Liu X, et al. Associations of anthropometric adiposity indexes with hypertension risk: A systematic review and meta-analysis including PURE-China. Medicine (Baltimore). 2018;97(48):e13262.
48. Biondi B. Thyroid and obesity: an intriguing relationship. J Clin Endocrin Metab. 2010;95:3614-7.
49. Rotondi M, Magri F, Chiovato L. Thyroid and obesity: not a one-way interaction. J Clin Endocrin Metab. 2011;96:344-6.
50. Laurberg P, Knudsen N, Andersen S, et al. Thyroid function and obesity. Eur Thyroid J. 2012;1:159-67.
51. Pearce E. Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes. 2012;19:408-13.
52. Duntas L, Biondi B. The interconnections between obesity, thyroid function, and autoimmunity: the multifold role of leptin. Thyroid. 2013;23:646-53.
53. Boscaro M, Arnaldi G. Approach to the patient with possible Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(9):3121-31.
54. Auriemma R. The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev Endocrinol Metab. 2018;13(2):99-106.
55. Dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity. 2011;19:800-5.
56. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of WHO/IDF Consultation. 2006.
57. Tang Z, Pham M, Hao Y et al. Sex, Age, and BMI Modulate the Association of Physical Examinations and Blood Biochemistry Parameters and NAFLD: A Retrospective Study on 1994 Cases Observed at Shuguang Hospital, China. Biomed Res Int. 2019;2019.
58. Pereira-Santos M, Costa PR, Assis AM, et al. Obesity and vitamin D deficiency: a systematic review and meta-analysis. Obes Rev. 2015;16(4):341-9.
59. Lotito A, Teramoto M, Cheung M, et al. Serum Parathyroid Hormone Responses to Vitamin D Supplementation in Overweight/Obese Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Nutrients. 2017;9(3). pii: E241
60. Hjelmesaeth J, Hofsø D, Aasheim ET, et al. Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study. Cardiovasc Diabetol. 2009;8(1):7.
61. Soares MJ, Ping-Delfos WC, Sherriff JL, et al. Vitamin D and parathyroid hormone in insulin resistance of abdominal obesity: cause or effect? Eur J Clin Nutr. 2011;65(12):1348-52.
62. Silidker MS, Cronan JJ, Scola FH, et al. Ultrasound evaluation of cholelithiasis in the morbidly obese. Gastrointestinal Radiol. 1988;13(1):345-6.
63. de Moura Almeida A, Cotrim HP, Barbosa DB, et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World J Gastroenterol. 2008;14(9):1415.
64. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):479-504.
65. Bozkurt B, Aguilar D, Deswal A, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016;134(23):e535-e578.
66. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200.
67. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985-3023.
68. Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient – 2013 Update: Cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring). 2013;21(0 1): S1–27. DOI:10.1002/oby.20461
69. Stoker D. Management of the bariatric surgery patient. Endocrinol Meatb Clin North Am. 2003;32:437-57.
70. Herpertz S, Kielmann R, Wolf A, et al. Do psychosocial variables predict weight loss or mental health after obesity surgery? A systematic review. Obes Res. 2004;12:1554-69.
71. Kalarchian M, Marcus M, Levine M, et al. Relationship of psychiatric disorders to 6-month outcomes after gastric bypass. Surg Obes Relat Dis. 2008;4:544-9.
72. Tindle H, Omalu B, Courcoulas A, et al. Risk of suicide after long-term follow-up from bariatric surgery. Am J Med. 2010;123:1036-42.
73. Sarwer D, Cohn N, Gibbons L, et al. Psychiatric diagnoses and psychiatric treatment among bariatric surgery candidates. Obes Surg. 2004;14:1148-56.
74. Van Hout G, Verschure S, Van Heck G. Psychosocial predictors of success following bariatric surgery. Obes Surg. 2005;15(4):552-60.
75. Wadden T, Sarwer D. Behavioral Assessment of Candidates for Bariatric Surgery: A Patient-Oriented Approach. Obesity. 2006;14 (Suppl):53S-62S.
76. Geerts W, Pineo G, Heit J, et al. Prevention of venous thromboembolism: the seventh ACCP conference of antithrombotic and thrombolytic therapy. Chest. 2004;126(Suppl. 3):338S-400S.
77. Martin L, Finigan K, Nolan T. Pregnancy after adjustable gastric banding. Obstetr Gynecol. 2000;95(6; Pt 1):927-30.
78. Gerrits E, Ceulemans R, van hee R, et al. Contraceptive treatment after biliopancreatic diversion needs consensus. Obes Surg. 2001;11:303-6.
79. Yang C, Lee W, Wang H, et al. The influence of Helicobacter pylori infection on the development of gastric ulcer in symptomatic patients after bariatric surgery. Obes Surg. 2006;16:735-9.
80. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
81. Blundell JE, Dulloo AG, Salvador J, et al. on behalf of the EASO SAB Working Group on BMI: Beyond BMI – phenotyping the obesities. Obes Facts. 2014;7:322-8.
82. Schwarz PE, Lindström J, Kissimova-Scarbeck K, et al. The European perspective of type 2 diabetes prevention: diabetes in Europe – prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes. 2008;116:167-72.
83. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: What fits whom? Diabetes Care. 2008;31(Suppl. 2):S269-S277.
84. Sampsel S, May J. Assessment and management of obesity and comorbid conditions. Dis Manag. 2007;1:252-65.
85. Jensen MD, Ryan DH, Apovian CM, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society: 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(Suppl. 2):S102-S138.
86. World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation (WHO Technical Report Series 894). Geneva, WHO, 1998. Available at: www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/ Accessed: 30.11.2015
87. Cefalu WT, Bray GA, Home PD, et al. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a Diabetes Care editors’ expert forum. Diabetes Care. 2015;38(8):1567-82.
88. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl. 3).
89. Shai I, Schwarzfuchs D, Henkin Y, et al., for the Dietary Intervention Randomized Controlled Trial (DIRECT) Group: Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359:229-41.
90. Dernini S, Berry EM. Mediterranean diet: from a healthy diet to a sustainable dietary pattern. Front Nutr. 2015;2:1-6.
91. Estruch R, Ros E, Salas-Salvadó J, et al. for the PREDIMED Study Investigators: Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279-90.
92. Avenell A, Brown T, McGee M, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet. 2004;17:317-35.
93. Dansinger ML, Gleason JA, Griffith JL, et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for Weight Loss and Heart Disease Risk ReductionA Randomized Trial. JAMA. 2005;293(1):43-53. DOI:10.1001/jama.293.1.43
94. Sharma M. Behavioural interventions for preventing and treating obesity in adults. Obes Rev. 2007;8:441-9.
95. Lang A, Froelicher ES. Management of overweight and obesity in adults: behavioral intervention for long-term weight loss and maintenance. Eur J Cardiovasc Nurs. 2006;5:102-14.
96. Moffitt R, Haynes A, Mohr P. Treatment beliefs and preferences for psychological therapies for weight management. J Clin Psychol. 2015;71:584-96.
97. Willis LH, Slentz CA, Bateman LA, et al. Effects of aerobic and/or resistance training on body mass and fat mass in overweight or obese adults. J Appl Physiol. 2012;113:1831-7.
98. Geliebter A, Christopher N, Ochner CN, et al. Obesity-related hormones and metabolic risk factors: a randomized trial of diet plus either strength or aerobic training versus diet alone in overweight participants. J Diabetes Obes. 2015;1:1-7.
99. Poirier P, Després JP. Exercise in weight management of obesity. Cardiol Clin. 2001;19:459-70.
100. Chin S-H, Kahathuduwa CN, Binks M. Physical activity and obesity: what we know and what we need to know. Obes Rev. 2016;17:1226-44.
101. Stephens SK, Cobiac LJ, Veerman JL. Improving diet and physical activity to reduce population prevalence of overweight and obesity: An overview of current evidence. Prev Med. 2014;62:167-78.
102. Malone M. Medications associated with weight gain. Ann Pharmacother. 2005;39(12):2046-55.
103. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl. 3).
104. Rucker D, Padwal R, Li S, et al. Long term pharmacotherapy for obesity and overweight updated meta-analysis. Br Med J. 2007;335:1194-9.
105. Avenell A, Broom J, Brown T, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004;8:iii-iv,1-182.
106. Bray GA. Medical treatment of obesity: the past, the present and the future. Best Pract Res Clin Gastroenterol. 2014;28:665-84.
107. Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol. 2015;31:142-52.
108. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61.
109. Toplak H, Ziegler O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab. 2005;7:699-708.
110. Williamson D, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in overweight white men aged 40–64 years. Am J Epidemiol. 1999;149:491-503.
111. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet. 2000;356:2119-25.
112. Dedov II, Melnichenko GA, Troshina EA, et al. Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. Obes Facts. 2018;11:335-43.
113. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Стратегия управления ожирением: итоги Всероссийской наблюдательной программы «ПримаВера». Ожирение и метаболизм. 2016;1:36-44 [Dedov II, Mel’nichenko GA, Romantsova TI. Strategiia upravleniia ozhireniem: itogi Vserossiiskoi nabliudatel’noi programmy “PrimaVera’. Ozhirenie i metabolizm. 2016;1:36-44 (in Russian)].
114. Sari R, Eray E, Ozdem S, Akbas H, Coban E. Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. Clin Exp Med. 2010;10(3):179-84.
115. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. DOI:10.1056/NEJMoa1411892
116. Le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-409. DOI:10.1016/s0140-6736(17)30069-7
117. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-9. DOI:10.1038/ij o.2016.52
118. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37:1443-51. DOI:10.1038/ijo.2013.120
119. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. DOI:10.1056/NEJMoa1603827
120. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric Surgery A Systematic Review and Meta-Analysis. JAMA. 2004;292(14):1724. DOI:10.1001/jama.292.14.1724
121. Fried M, Yumuk V, Oppert J-M, et al. Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery. Obesity Facts. 2013;6(5):449-68. DOI:10.1159/000355480
122. Guidelines for Laparoscopic and Open Surgical Treatment of Morbid Obesity. Obes Surg. 2000;10(4):378-9. DOI:10.1381/096089200321629184
123. American College of Endocrinology (ACE), American Association of Clinical Endocrinologists (AACE): AACE/ACE position statement on the prevention, diagnosis and treatment of obesity. Jacksonville: American Association of Clinical Endocrinologists, 1998.
124. Buchwald H, Estok R, Fahrbach K, et al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. Am J Med. 2009;122(3):248-256.e245. DOI:10.1016/j.amjmed.2008.09.041
125. Apovian CM, Baker C, Ludwig DS, et al. Best practice guidelines in pediatric/adolescent weight loss surgery. Obes Res. 2005;13:274-82.
126. Inge TH, Krebs NF, Garcia VF, et al. Bariatric surgery for severely overweight adolescents: concerns and recommendations. Pediatrics. 2004;114:217-23.
127. Sugerman HJ, Sugerman EL, DeMaria EJ, et al. Bariatric surgery for severely obese adolescents. J Gastrointest Surg. 2003;7:102-7.
128. Dolan K, Creighton L, Hopkins G, Fielding G. Laparoscopic gastric banding in morbidly obese adolescents. Obes Surg. 2003;13:101-4.
129. Stanford A, Glascock JM, Eid GM, et al. laparoscopic Roux-en-Y gastric bypass in morbidly obese adolescents. J Pediatr Surg. 2003;38:430-3.
130. Widhalm K, Dietrich S, Prager G. Adjustable gastric banding surgery in morbidly obese adolescents: experience with 8 patients. Int J Obes Relat Metab Disord. 2004;28(Suppl. 3):42S-48S.
131. Silberhummer GR, Miller K, Kriwanek S, et al. Laparoscopic adjustable gastric banding in adolescents: the Austrian experience. Obes Surg. 2006;16:1062-7.
132. Capella JF, Capella RF. Bariatric surgery in adolescence: is this the best age to operate? Obes Surg. 2003;13:826-32.
133. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23(1):93-102. DOI:10.1007/s11695-012- 0802-1
134. Mingrone G, Castagneto-Gissey L. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab. 2009;35:518-23.
135. Peterli R, Wolnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250:234-41.
136. Hofso D, Nordstrand N, Johnson LK, et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2010;163:735-45.
137. Schauer PR, Kashyap S, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese diabetic patients. N Engl J Med. 2012;366:1567-76.
138. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85.
139. Hofso D, Jenssen T, Bollerslev J, et al. Beta cell function after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2011;164:231-8.
140. Hsu L, Benotti P, Dwyer J. Nonsurgical factors that influence the outcome of bariatric surgery: a review. Psychosom Med. 1998;60:338-46.
141. Fried M, Ribaric G, Buchwald JN, et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI < 35 kg/M2: an integrative review of early studies. Obes Surg. 2010;20:776-90.
142. Lee WJ, Chong K, Chen CY, et al. Diabetes remission and insulin secretion after gastric bypass in patients with body mass index < 35 kg/M2. Obes Surg. 2011;21:889-95.
143. Demaria EJ, Winegar DA, Pate VW, et al. Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the Bariatric Outcomes Longitudinal Database. Ann Surg. 2010;252:559-66.
144. Lee WJ, Ser KH, Chong K, et al. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion. Surgery. 2010;147:664-9.
145. Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133-5.
146. Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric Surgery for Weight Loss and Glycemic Control in Nonmorbidly Obese Adults With Diabetes. JAMA. 2013;309(21):2250-61.
147. AACE/ACE Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan – 2015. Endocr Pract. 2015;21(Suppl. 1).
148. Dronge A, Percal H, Kancir S, et al. Long-term glycemic control and postoperative infectious complications. Arch Surg. 2006;141:375-80.
149. Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010;95:4823-43.
150. Brolin R, Leung M. Survey of vitamin and mineral supplementation after gastric bypass and biliopancreatic diversion for morbid obesity. Obes Surg. 1999;9:150-4.
151. Skroubis G, Sakellapoulos G, Pouggouras K, et al. Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with Roux-en-Y gastric bypass. Obes Surg. 2002;12:551-8.
152. Gasteyger C, Suter H, Gaillard R, et al. Nutritional deficiencies after Roux-en-Y gastric bypass for morbid obesity often cannot be prevented by standart multivitamin supplementation. Am J Clin Nutr. 2008;87:1128-33.
153. Aasheim E, Hofso D, Hjelmesaeth J, et al. Vitamin status in morbidly obese patients: a cross-sectional study. Am J Clin Nutr. 2008;87:362-9.

________________________________________________

1. World Health Organization. Obesity: preventing and managing the global epidemic. Geneva: WHO, 1997.
2. Biddle S, García Bengoechea E, Pedisic Z, et al. Screen Time, Other Sedentary Behaviours, and Obesity Risk in Adults: A Review of Reviews. Curr Obes Rep. 2017;6(2):134-47.
3. Arroyo-Johnson C, Mincey KD. Obesity Epidemiology Worldwide. Gastroenterol Clin North Am. 2016;45(4):571-9.
4. Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017;376(3):254-66.
5. Yeo G, Heisler L. Unraveling the brain regulation of appetite: lessons from genetics. Nat Neurosci. 2012;15(10):1343-9.
6. Lam D, Garfield A, Marston O, et al. Brain serotonin system in the coordination of food intake and body weight. Pharmacol Biochem Behav. 2010;97(1):84-91.
7. Campbell E, Franks A, Joseph P. Adolescent obesity in the past decade: A systematic review of genetics and determinants of food choice. J Am Assoc Nurse Pract. 2019;31(6):344-51.
8. Zhi C, Huang J, Wang J, et al. Connection between gut microbiome and the development of obesity. Eur J Clin Microbiol Infect Dis. 2019; Jul 31. DOI:10.1007/s10096-019-03623-x
9. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116:1784-92.
10. Bastard J, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4-12.
11. Montanari T, Pošćić N, Colitti M. Factors involved in white-to-brown adipose tissue conversion and in thermogenesis: a review. Obes Rev. 2017;18(5):495-513.
12. Fernández-Verdejo R, Marlatt K, Ravussin E, Galgani J. Contribution of brown adipose tissue to human energy metabolism. Mol Aspects Med. 2019; Jul 16. DOI:10.1016/j.mam.2019.07.003
13. Must A, Spadano J, Coakley E, et al. The disease burden associated with overweight and obesity. JAMA. 1999;282:1523-9.
14. Guh D, Zhang W, Bansback N, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.
15. Lenz M, Richter T, Muhlhauser I. The morbidity and mortality associated with overweight and obesity in adulthood: a systematic review. Dtsch Arztebl Int. 2009;106:641-8.
16. Alberti K, Zimmet P, Shaw J. IDF Epidemiology Task Force Consensus Group. The metabolic syndrome a new worldwide definition. Lancet. 2005;366:1059-62.
17. Available at: https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight
18. Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond). 2008;32(9):1431-7.
19. Dedov II, Shestakova MV, Galstian GR. Rasprostranennost’ sakharnogo diabeta 2 tipa u vzroslogo naseleniia Rossii (issledovanie NATION). Sakharnyi diabet. 2016;19(2):104-12 (in Russian).
20. Obesity: etiology, pathogenesis, clinical aspects. Edited by I.I. Dedov, G.A. Melnichenko. Moscow: Medical Information Agency, 2004; р. 16-21 (in Russian).
21. Garvey W, Garber A, Mechanick J, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the 2014 Advanced Framework for a New Diagnosis of Obesity as a Chronic Disease. Endocr Pract. 2014;20:977-89.
22. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. Geneva: World Health Organization, 1995; р. 329.
23. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205-11.
24. Swinburn BA, Craig PL, Daniel R, Dent DP, Strauss BJ. Body composition differences between Polynesians and Caucasians assessed by bioelectrical impedance. Int J Obes Relat Metab Disord. 1996;20:889-94.
25. Forbes GB, Reina JC. Adult lean body mass decline with age: some longitudinal observations. Metabolism. 1970;19:653-63.
26. Rolland-Cachera MF, Cole TJ, Sempé M, et al. Body mass index variations – centiles from birth to 87 years. Eur J Clin Nutr. 1991;45:13-21.
27. Ross R, Shaw KD, Rissanen J, et al. Sex differences in lean and adipose tissue distribution by magnetic resonance imaging: anthropometric relationships. Am J Clin Nutr. 1994;59:1277-85.
28. Norgan NG, Jones PRM. The effect of standardizing the body mass index for relative sitting height. Int J Obes Relat Metab Disord. 1995;19:206-8.
29. Lean MEJ, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. Br Med J. 1995;311:158-61.
30. Han TS, et al. Waist circumference relates to intra-abdominal fat mass better than waist: hip ratio in women. Proceedings of the Nutrition Society. 1995;54:152A.
31. Pouliot MC, Després JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol. 1994;73:460-8.
32. Ross R, Léger L, Morris D, et al. Quantification of adipose tissue by MRI: relationship with anthropometric variables. J Appl Physiol. 1992;72:787-95.
33. Lean MEJ, Han TS, Deurenberg P. Predicting body composition by densitometry from simple anthropometric measurements. Am J Clin Nutr. 1996;63:4-14.
34. Han TS, Richmond P, Avenell A, Lean ME. Waist circumference reduction and cardiovascular benefits during weight loss in women. Int J Obes Relat Metab Disord. 1997;21:127-34.
35. Finucane MM, Stevens GA, Cowan MJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377(9765):557-67.
36. Emerging Risk Factors Collaboration, Wormser D, Kaptoge S, Di Angelantonio E, et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011;377(9771):1085-95.
37. Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007;25(9):1751-62. DOI:10.1097/HJH.0b013e3282f0580f
38. Masa JF, Pépin JL, Borel JC, et al. Obesity hypoventilation syndrome. Eur Respir Rev. 2019;28(151). pii: 180097
39. Macavei VM, Spurling KJ, Loft J, Makker HK. Diagnostic predictors of obesity-hypoventilation syndrome in patients suspected of having sleep disordered breathing. J Clin Sleep Med. 2013;9:879-84.
40. Camilleri M, Malhi H, Acosta A. Gastrointestinal Complications of Obesity. Gastroenterology. 2017;152(7):1656-70.
41. Khatua B, El-Kurdi B, Singh VP. Obesity and pancreatitis. Curr Opin Gastroenterol. 2017;33(5):374-82.
42. Escobar-Morreale HF, Santacruz E, Luque-Ramírez M, Botella Carretero JI. Prevalence of “obesity-associated gonadal dysfunction” in severely obese men and women and its resolution after bariatric surgery: a systematic review and meta-analysis. Hum Reprod Update. 2017; 23 (4): 390–408.
43. Daniel E, Newell-Price J. Cushing’s syndrome. Medicine. 2017;45(8):475-9.
44. Stuart CA, Driscoll MS, Lundquist KF, et al. Acanthosis nigricans. J Basic Clin Physiol Pharmacol. 1998;9(2-4):407-18.
45. Rohde K, Keller M, la Cour Poulsen L, et al. Genetics and epigenetics in obesity. Metabolism. 2019;92:37-50.
46. Mirzababaei A, Mozaffari H, Shab-Bidar S, et al. Risk of hypertension among different metabolic phenotypes: a systematic review and meta-analysis of prospective cohort studies. J Hum Hypertens. 2019;33(5):365-77.
47. Deng G, Yin L, Liu W, Liu X, et al. Associations of anthropometric adiposity indexes with hypertension risk: A systematic review and meta-analysis including PURE-China. Medicine (Baltimore). 2018;97(48):e13262.
48. Biondi B. Thyroid and obesity: an intriguing relationship. J Clin Endocrin Metab. 2010;95:3614-7.
49. Rotondi M, Magri F, Chiovato L. Thyroid and obesity: not a one-way interaction. J Clin Endocrin Metab. 2011;96:344-6.
50. Laurberg P, Knudsen N, Andersen S, et al. Thyroid function and obesity. Eur Thyroid J. 2012;1:159-67.
51. Pearce E. Thyroid hormone and obesity. Curr Opin Endocrinol Diabetes Obes. 2012;19:408-13.
52. Duntas L, Biondi B. The interconnections between obesity, thyroid function, and autoimmunity: the multifold role of leptin. Thyroid. 2013;23:646-53.
53. Boscaro M, Arnaldi G. Approach to the patient with possible Cushing’s syndrome. J Clin Endocrinol Metab. 2009;94(9):3121-31.
54. Auriemma R. The effects of hyperprolactinemia and its control on metabolic diseases. Expert Rev Endocrinol Metab. 2018;13(2):99-106.
55. Dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity. 2011;19:800-5.
56. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. Report of WHO/IDF Consultation. 2006.
57. Tang Z, Pham M, Hao Y et al. Sex, Age, and BMI Modulate the Association of Physical Examinations and Blood Biochemistry Parameters and NAFLD: A Retrospective Study on 1994 Cases Observed at Shuguang Hospital, China. Biomed Res Int. 2019;2019.
58. Pereira-Santos M, Costa PR, Assis AM, et al. Obesity and vitamin D deficiency: a systematic review and meta-analysis. Obes Rev. 2015;16(4):341-9.
59. Lotito A, Teramoto M, Cheung M, et al. Serum Parathyroid Hormone Responses to Vitamin D Supplementation in Overweight/Obese Adults: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Nutrients. 2017;9(3). pii: E241
60. Hjelmesaeth J, Hofsø D, Aasheim ET, et al. Parathyroid hormone, but not vitamin D, is associated with the metabolic syndrome in morbidly obese women and men: a cross-sectional study. Cardiovasc Diabetol. 2009;8(1):7.
61. Soares MJ, Ping-Delfos WC, Sherriff JL, et al. Vitamin D and parathyroid hormone in insulin resistance of abdominal obesity: cause or effect? Eur J Clin Nutr. 2011;65(12):1348-52.
62. Silidker MS, Cronan JJ, Scola FH, et al. Ultrasound evaluation of cholelithiasis in the morbidly obese. Gastrointestinal Radiol. 1988;13(1):345-6.
63. de Moura Almeida A, Cotrim HP, Barbosa DB, et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World J Gastroenterol. 2008;14(9):1415.
64. Kapur VK, Auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):479-504.
65. Bozkurt B, Aguilar D, Deswal A, et al. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016;134(23):e535-e578.
66. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200.
67. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985-3023.
68. Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Surgery Patient – 2013 Update: Cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring). 2013;21(0 1): S1–27. DOI:10.1002/oby.20461
69. Stoker D. Management of the bariatric surgery patient. Endocrinol Meatb Clin North Am. 2003;32:437-57.
70. Herpertz S, Kielmann R, Wolf A, et al. Do psychosocial variables predict weight loss or mental health after obesity surgery? A systematic review. Obes Res. 2004;12:1554-69.
71. Kalarchian M, Marcus M, Levine M, et al. Relationship of psychiatric disorders to 6-month outcomes after gastric bypass. Surg Obes Relat Dis. 2008;4:544-9.
72. Tindle H, Omalu B, Courcoulas A, et al. Risk of suicide after long-term follow-up from bariatric surgery. Am J Med. 2010;123:1036-42.
73. Sarwer D, Cohn N, Gibbons L, et al. Psychiatric diagnoses and psychiatric treatment among bariatric surgery candidates. Obes Surg. 2004;14:1148-56.
74. Van Hout G, Verschure S, Van Heck G. Psychosocial predictors of success following bariatric surgery. Obes Surg. 2005;15(4):552-60.
75. Wadden T, Sarwer D. Behavioral Assessment of Candidates for Bariatric Surgery: A Patient-Oriented Approach. Obesity. 2006;14 (Suppl):53S-62S.
76. Geerts W, Pineo G, Heit J, et al. Prevention of venous thromboembolism: the seventh ACCP conference of antithrombotic and thrombolytic therapy. Chest. 2004;126(Suppl. 3):338S-400S.
77. Martin L, Finigan K, Nolan T. Pregnancy after adjustable gastric banding. Obstetr Gynecol. 2000;95(6; Pt 1):927-30.
78. Gerrits E, Ceulemans R, van hee R, et al. Contraceptive treatment after biliopancreatic diversion needs consensus. Obes Surg. 2001;11:303-6.
79. Yang C, Lee W, Wang H, et al. The influence of Helicobacter pylori infection on the development of gastric ulcer in symptomatic patients after bariatric surgery. Obes Surg. 2006;16:735-9.
80. Knowler WC, Barrett-Connor E, Fowler SE, et al. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
81. Blundell JE, Dulloo AG, Salvador J, et al. on behalf of the EASO SAB Working Group on BMI: Beyond BMI – phenotyping the obesities. Obes Facts. 2014;7:322-8.
82. Schwarz PE, Lindström J, Kissimova-Scarbeck K, et al. The European perspective of type 2 diabetes prevention: diabetes in Europe – prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. Exp Clin Endocrinol Diabetes. 2008;116:167-72.
83. Hainer V, Toplak H, Mitrakou A. Treatment modalities of obesity: What fits whom? Diabetes Care. 2008;31(Suppl. 2):S269-S277.
84. Sampsel S, May J. Assessment and management of obesity and comorbid conditions. Dis Manag. 2007;1:252-65.
85. Jensen MD, Ryan DH, Apovian CM, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society: 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(Suppl. 2):S102-S138.
86. World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Report of a WHO Consultation (WHO Technical Report Series 894). Geneva, WHO, 1998. Available at: www.who.int/nutrition/publications/obesity/WHO_TRS_894/en/ Accessed: 30.11.2015
87. Cefalu WT, Bray GA, Home PD, et al. Advances in the science, treatment, and prevention of the disease of obesity: reflections from a Diabetes Care editors’ expert forum. Diabetes Care. 2015;38(8):1567-82.
88. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl. 3).
89. Shai I, Schwarzfuchs D, Henkin Y, et al., for the Dietary Intervention Randomized Controlled Trial (DIRECT) Group: Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359:229-41.
90. Dernini S, Berry EM. Mediterranean diet: from a healthy diet to a sustainable dietary pattern. Front Nutr. 2015;2:1-6.
91. Estruch R, Ros E, Salas-Salvadó J, et al. for the PREDIMED Study Investigators: Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279-90.
92. Avenell A, Brown T, McGee M, et al. What are the long-term benefits of weight reducing diets in adults? A systematic review of randomized controlled trials. J Hum Nutr Diet. 2004;17:317-35.
93. Dansinger ML, Gleason JA, Griffith JL, et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone Diets for Weight Loss and Heart Disease Risk ReductionA Randomized Trial. JAMA. 2005;293(1):43-53. DOI:10.1001/jama.293.1.43
94. Sharma M. Behavioural interventions for preventing and treating obesity in adults. Obes Rev. 2007;8:441-9.
95. Lang A, Froelicher ES. Management of overweight and obesity in adults: behavioral intervention for long-term weight loss and maintenance. Eur J Cardiovasc Nurs. 2006;5:102-14.
96. Moffitt R, Haynes A, Mohr P. Treatment beliefs and preferences for psychological therapies for weight management. J Clin Psychol. 2015;71:584-96.
97. Willis LH, Slentz CA, Bateman LA, et al. Effects of aerobic and/or resistance training on body mass and fat mass in overweight or obese adults. J Appl Physiol. 2012;113:1831-7.
98. Geliebter A, Christopher N, Ochner CN, et al. Obesity-related hormones and metabolic risk factors: a randomized trial of diet plus either strength or aerobic training versus diet alone in overweight participants. J Diabetes Obes. 2015;1:1-7.
99. Poirier P, Després JP. Exercise in weight management of obesity. Cardiol Clin. 2001;19:459-70.
100. Chin S-H, Kahathuduwa CN, Binks M. Physical activity and obesity: what we know and what we need to know. Obes Rev. 2016;17:1226-44.
101. Stephens SK, Cobiac LJ, Veerman JL. Improving diet and physical activity to reduce population prevalence of overweight and obesity: An overview of current evidence. Prev Med. 2014;62:167-78.
102. Malone M. Medications associated with weight gain. Ann Pharmacother. 2005;39(12):2046-55.
103. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl. 3).
104. Rucker D, Padwal R, Li S, et al. Long term pharmacotherapy for obesity and overweight updated meta-analysis. Br Med J. 2007;335:1194-9.
105. Avenell A, Broom J, Brown T, et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess. 2004;8:iii-iv,1-182.
106. Bray GA. Medical treatment of obesity: the past, the present and the future. Best Pract Res Clin Gastroenterol. 2014;28:665-84.
107. Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. Can J Cardiol. 2015;31:142-52.
108. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155-61.
109. Toplak H, Ziegler O, Keller U, et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab. 2005;7:699-708.
110. Williamson D, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in overweight white men aged 40–64 years. Am J Epidemiol. 1999;149:491-503.
111. James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet. 2000;356:2119-25.
112. Dedov II, Melnichenko GA, Troshina EA, et al. Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. Obes Facts. 2018;11:335-43.
113. Dedov II, Mel’nichenko GA, Romantsova TI. Strategiia upravleniia ozhireniem: itogi Vserossiiskoi nabliudatel’noi programmy “PrimaVera’. Ozhirenie i metabolizm. 2016;1:36-44 (in Russian).
114. Sari R, Eray E, Ozdem S, Akbas H, Coban E. Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. Clin Exp Med. 2010;10(3):179-84.
115. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. DOI:10.1056/NEJMoa1411892
116. Le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399-409. DOI:10.1016/s0140-6736(17)30069-7
117. Blackman A, Foster GD, Zammit G, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310-9. DOI:10.1038/ij o.2016.52
118. Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study. Int J Obes (Lond). 2013;37:1443-51. DOI:10.1038/ijo.2013.120
119. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22. DOI:10.1056/NEJMoa1603827
120. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric Surgery A Systematic Review and Meta-Analysis. JAMA. 2004;292(14):1724. DOI:10.1001/jama.292.14.1724
121. Fried M, Yumuk V, Oppert J-M, et al. Interdisciplinary European Guidelines on Metabolic and Bariatric Surgery. Obesity Facts. 2013;6(5):449-68. DOI:10.1159/000355480
122. Guidelines for Laparoscopic and Open Surgical Treatment of Morbid Obesity. Obes Surg. 2000;10(4):378-9. DOI:10.1381/096089200321629184
123. American College of Endocrinology (ACE), American Association of Clinical Endocrinologists (AACE): AACE/ACE position statement on the prevention, diagnosis and treatment of obesity. Jacksonville: American Association of Clinical Endocrinologists, 1998.
124. Buchwald H, Estok R, Fahrbach K, et al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. Am J Med. 2009;122(3):248-256.e245. DOI:10.1016/j.amjmed.2008.09.041
125. Apovian CM, Baker C, Ludwig DS, et al. Best practice guidelines in pediatric/adolescent weight loss surgery. Obes Res. 2005;13:274-82.
126. Inge TH, Krebs NF, Garcia VF, et al. Bariatric surgery for severely overweight adolescents: concerns and recommendations. Pediatrics. 2004;114:217-23.
127. Sugerman HJ, Sugerman EL, DeMaria EJ, et al. Bariatric surgery for severely obese adolescents. J Gastrointest Surg. 2003;7:102-7.
128. Dolan K, Creighton L, Hopkins G, Fielding G. Laparoscopic gastric banding in morbidly obese adolescents. Obes Surg. 2003;13:101-4.
129. Stanford A, Glascock JM, Eid GM, et al. laparoscopic Roux-en-Y gastric bypass in morbidly obese adolescents. J Pediatr Surg. 2003;38:430-3.
130. Widhalm K, Dietrich S, Prager G. Adjustable gastric banding surgery in morbidly obese adolescents: experience with 8 patients. Int J Obes Relat Metab Disord. 2004;28(Suppl. 3):42S-48S.
131. Silberhummer GR, Miller K, Kriwanek S, et al. Laparoscopic adjustable gastric banding in adolescents: the Austrian experience. Obes Surg. 2006;16:1062-7.
132. Capella JF, Capella RF. Bariatric surgery in adolescence: is this the best age to operate? Obes Surg. 2003;13:826-32.
133. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23(1):93-102. DOI:10.1007/s11695-012- 0802-1
134. Mingrone G, Castagneto-Gissey L. Mechanisms of early improvement/resolution of type 2 diabetes after bariatric surgery. Diabetes Metab. 2009;35:518-23.
135. Peterli R, Wolnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009;250:234-41.
136. Hofso D, Nordstrand N, Johnson LK, et al. Obesity-related cardiovascular risk factors after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2010;163:735-45.
137. Schauer PR, Kashyap S, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese diabetic patients. N Engl J Med. 2012;366:1567-76.
138. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85.
139. Hofso D, Jenssen T, Bollerslev J, et al. Beta cell function after weight loss: a clinical trial comparing gastric bypass surgery and intensive lifestyle intervention. Eur J Endocrinol. 2011;164:231-8.
140. Hsu L, Benotti P, Dwyer J. Nonsurgical factors that influence the outcome of bariatric surgery: a review. Psychosom Med. 1998;60:338-46.
141. Fried M, Ribaric G, Buchwald JN, et al. Metabolic surgery for the treatment of type 2 diabetes in patients with BMI < 35 kg/M2: an integrative review of early studies. Obes Surg. 2010;20:776-90.
142. Lee WJ, Chong K, Chen CY, et al. Diabetes remission and insulin secretion after gastric bypass in patients with body mass index < 35 kg/M2. Obes Surg. 2011;21:889-95.
143. Demaria EJ, Winegar DA, Pate VW, et al. Early postoperative outcomes of metabolic surgery to treat diabetes from sites participating in the ASMBS bariatric surgery center of excellence program as reported in the Bariatric Outcomes Longitudinal Database. Ann Surg. 2010;252:559-66.
144. Lee WJ, Ser KH, Chong K, et al. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion. Surgery. 2010;147:664-9.
145. Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133-5.
146. Maggard-Gibbons M, Maglione M, Livhits M, et al. Bariatric Surgery for Weight Loss and Glycemic Control in Nonmorbidly Obese Adults With Diabetes. JAMA. 2013;309(21):2250-61.
147. AACE/ACE Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan – 2015. Endocr Pract. 2015;21(Suppl. 1).
148. Dronge A, Percal H, Kancir S, et al. Long-term glycemic control and postoperative infectious complications. Arch Surg. 2006;141:375-80.
149. Endocrine and Nutritional Management of the Post-Bariatric Surgery Patient: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010;95:4823-43.
150. Brolin R, Leung M. Survey of vitamin and mineral supplementation after gastric bypass and biliopancreatic diversion for morbid obesity. Obes Surg. 1999;9:150-4.
151. Skroubis G, Sakellapoulos G, Pouggouras K, et al. Comparison of nutritional deficiencies after Roux-en-Y gastric bypass and after biliopancreatic diversion with Roux-en-Y gastric bypass. Obes Surg. 2002;12:551-8.
152. Gasteyger C, Suter H, Gaillard R, et al. Nutritional deficiencies after Roux-en-Y gastric bypass for morbid obesity often cannot be prevented by standart multivitamin supplementation. Am J Clin Nutr. 2008;87:1128-33.
153. Aasheim E, Hofso D, Hjelmesaeth J, et al. Vitamin status in morbidly obese patients: a cross-sectional study. Am J Clin Nutr. 2008;87:362-9.

И.И. Дедов1, Н.Г. Мокрышева1, Г.А. Мельниченко1, Е.А. Трошина1, Н.В. Мазурина1, Е.В. Ершова1, К.А. Комшилова1, Е.Н. Андреева1, М.Б. Анциферов2, Е.В. Бирюкова3, Н.С. Бордан4, Г.Р. Вагапова5, А.Р. Волкова6, Н.И. Волкова7, А.П. Волынкина8, Ф.Х. Дзгоева1, Т.П. Киселева9, А.Е. Неймарк10, Т.И. Романцова11, Л.А. Руяткина12, Л.А. Суплотова13, Ю.Ш. Халимов14, Ю.И. Яшков15

1 ФГБУ «Национальный медицинский исследовательский центр эндокринологии» Минздрава России, Москва, Россия;
2 ГБУЗ «Эндокринологический диспансер» Департамента здравоохранения г. Москвы, Москва, Россия;
3 ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России, Москва, Россия;
4 АО «Институт пластической хирургии и косметологии», Москва, Россия;
5 Казанская государственная медицинская академия – филиал ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования», Казань, Россия;
6 ФГБОУ ВО «Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова» Минздрава России, Санкт-Петербург, Россия;
7 ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России, Ростов-на-Дону, Россия;
8 ФГБОУ ВО «Воронежский государственный медицинский университет им. Н.Н. Бурденко» Минздрава России, Воронеж, Россия;
9 ФГБОУ ВО «Уральский государственный медицинский университет» Минздрава России, Екатеринбург, Россия;
10 ФГБУ «Национальный медицинский исследовательский центр им. В.А. Алмазова» Минздрава России, Санкт-Петербург, Россия;
11 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
12 ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России, Новосибирск, Россия;
13 ФГБОУ ВО «Тюменский государственный медицинский университет» Минздрава России, Тюмень, Россия;
14 ФГБВОУ ВО «Военно-медицинская академия им. С.М. Кирова» Минобороны России, Санкт-Петербург, Россия;
15 AО «Центр эндохирургии и литотрипсии», Москва, Россия

________________________________________________

Ivan I. Dedov1, Natalia G. Mokrysheva1, Galina A. Mel’nichenko1, Ekaterina A. Troshina1, Natalya V. Mazurina1, Ekaterina V. Ershova1, Kseniya A. Komshilova1, Elena N. Andreeva1, Mikhail B. Antsiferov2, Elena V. Biriukova3, Natalia S. Bordan4, Gulnar R. Vagapova5, Anna R. Volkova6, Natalia I. Volkova7, Anna P. Volynkina8, Fatima Kh. Dzgoeva1, Tatiana P. Kiseleva9, Aleksandr E. Neimark10, Tatiana I. Romantsova11, Liudmila A. Ruiatkina12, Liudmila A. Suplotova13, Yury Sh. Khalimov14, Yury I. Yashkov15

1 Endocrinology Research Centre, Moscow, Russia;
2 Endocrinological Dispensary, Moscow, Russia;
3 Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russia;
4 Institute of Plastic Surgery and Cosmetology, Moscow, Russia;
5 Kazan State Medical Academy – branch of Russian Medical Academy of Continuous Professional Education, Kazan, Russia;
6 Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia;
7 Rostov State Medical University, Rostov-on-Don, Russia;
8 Burdenko Voronezh State Medical University, Voronezh, Russia;
9 Ural State Medical University, Ekaterinburg, Russia;
10 Almazov National Medical Research Centre, Saint Petersburg, Russia;
11 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
12 Novosibirsk State Medical University, Novosibirsk, Russia;
13 Tyumen State Medical University, Tyumen, Russia;
14 Kirov Military Medical Academy, Saint Petersburg, Russia;
15 Endosurgery and Lithotripsy Center, Moscow, Russia